ArticleSaudi journal of biological sciences2017
On the significance of Tim-3 expression in pancreatic cancer.
Article in Saudi journal of biological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation.Frontiers in oncology · 2021Pooled it
- Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation.Frontiers in oncology · 2020Pooled it
- Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-rasGastroenterology · 2026Article
- Targeting pancreatic cancer with adenoviral vectors equipped with transgenes.Molecular cancer therapeutics · 2026Article
- Article
- Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms.The Journal of pathology · 2025Article
- It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Review
- TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer.American journal of cancer research · 2024Article
- Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance.Current cancer drug targets · 2024Review
- Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.Cancer medicine · 2024Article
- Article
- Occupational Low-Dose Radiation Affects the Expression of Immune Checkpoint of Medical Radiologists.International journal of environmental research and public health · 2022Article
- Nanoparticle-based immunotherapy of pancreatic cancer.Frontiers in molecular biosciences · 2022Review
- Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Review
- TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Article
- Mechanisms of T-Cell Exhaustion in Pancreatic Cancer.Cancers · 2020Review
- Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.OncoTargets and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aim to explore the connection between Tim-3 expression in both cancerous pancreatic and pericarcinous tissues and the clinicopathological features of pancreatic cancer. We will also preliminarily assess the role and significance of Tim-3 in the diagnosis, treatment, and prognosis of pancreatic cancer.
methodsCancerous pancreatic and pericarcinous tissues from 50 patients with pancreatic cancer and six healthy pancreatic tissues were collected from the pathological specimens of traumatic patients to distinguish Tim-3 expression using immunohistochemistry. Tim-3 expression was observed to be correlated with cell invasion, metastasis, and recurrence of pancreatic cancer.
results1. For the immunohistochemical method, Tim-3 expression in pancreatic cancer tissues was observed to be elevated and statistically significant (P < .01) compared to pericarcinous and normal pancreatic tissues. No statistically significant difference (P > .05) was observed between Tim-3 expression in pericarcinous and normal pancreatic tissues. 2. While Tim-3 expression was observed to be closely related to the history of smoking, fasting blood glucose, tumor size, TNM stage, it was not observed to be related to gender, age, tumor location, pathological type, and degree of tumor differentiation.
conclusion1. Tim-3 expression in pancreatic cancer tissues was high. 2. The high Tim-3 expression in pancreatic cancer tissues may be closely related to cell invasion, metastasis, and the recurrence of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.